Sanofi (NASDAQ:SNY) Rating Lowered to Buy at StockNews.com

Sanofi (NASDAQ:SNY) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday.

Separately, Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Hold” and a consensus price target of $57.50.

Sanofi Trading Down 1.2 %

NASDAQ SNY opened at $56.75 on Wednesday. The stock has a market cap of $143.73 billion, a P/E ratio of 28.52, a P/E/G ratio of 1.64 and a beta of 0.60. The stock’s fifty day moving average price is $53.52 and its 200-day moving average price is $50.08. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter last year, the firm earned $0.95 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, equities analysts forecast that Sanofi will post 4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. TCTC Holdings LLC boosted its holdings in shares of Sanofi by 28.0% during the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after purchasing an additional 210 shares during the last quarter. HB Wealth Management LLC grew its holdings in Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after buying an additional 221 shares in the last quarter. Wynn Capital LLC increased its stake in Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after acquiring an additional 226 shares during the last quarter. Insigneo Advisory Services LLC raised its holdings in shares of Sanofi by 3.3% during the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after acquiring an additional 228 shares in the last quarter. Finally, Angeles Investment Advisors LLC boosted its position in shares of Sanofi by 2.1% during the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock valued at $598,000 after acquiring an additional 244 shares during the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.